Cancer
Conditions
Interventions
None listed
Sponsors
Institute of Science Tokyo Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with cancer (more than or equal to 80%) 2. Patients without delirium before intervention 3. Studies examining the efficacy or safety of orexin receptor antagonists for the prevention of delirium in adult cancer patients The study design to be considered for inclusion is as follows: 1. If there were at least two randomized controlled trial (RCT)s, inclusion was completed. 2. If there were less than 2 RCTs, we included non-RCTs or observational studies with control groups. 3. If there were no RCTs/non-RCTs/observational studies with control groups, single-arm observational studies were considered for inclusion.
Exclusion criteria
Exclusion criteria: 1. Duplicated publications 2. Conference proceedings 3. Reviews which are not based on systematic review 4. Study protocols 5. Case reports and case series 6. Articles written in languages other than English or Japanese
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of delirium | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Severity of delirium 2. Somnolence 3. Tumbling and falls | — |
Countries
Japan
Contacts
Public ContactShuntaro Yasuda
Institute of Science Tokyo Hospital Department of Pharmacy
Outcome results
None listed